VivoSeq
Other

Drug

0

Pipeline Programs↗

28

Active Trials↗

48

Companies Involved↗

Drug is an early-stage landscape with 0 programs across 48 companies. The most active players are GSK, Bristol-Myers Squibb, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

374

clinical trials

Completed301 · 80%
Unknown status20 · 5%
Recruiting16 · 4%
Terminated14 · 4%
Active, not recruiting8 · 2%
Withdrawn8 · 2%
Other7 · 2%

Clinical Trials

Trial Activity

374 trials

Special Drug Use-results Surveillance of Tafinlar/Mekinist
Recruiting·Novartis logoNovartis·N/A·NCT06262919·110 enrolled
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
Recruiting·—·Phase 4·NCT06528431·180 enrolled
Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Recruiting·KKissei Pharmaceutical Co., Ltd.·N/A·NCT06757257·149 enrolled
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
Recruiting·Bayer logoBayer·Phase 1·NCT07176728·16 enrolled
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT07283263·106 enrolled
Severe Bullous Drug Eruption and Filgrastim
Recruiting·HHospices Civils de Lyon·Phase 2/3·NCT04651439·42 enrolled
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT06174987·50 enrolled
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT05866627·76 enrolled
Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room
Recruiting·NNantes University Hospital·Phase 3·NCT06733129·1,218 enrolled
Beta-Adrenergic Modulation of Drug Cue Reactivity
Recruiting·UUniversity of Oklahoma·Phase 4·NCT05587361·80 enrolled
Special Drug Use-results Survey for Long-term Use（Avacopan）
Recruiting·KKissei Pharmaceutical Co., Ltd.·N/A·NCT06758271·250 enrolled
LUPKYNIS Drug-use Results Survey
Recruiting·Otsuka logoOtsuka·N/A·NCT07053891·400 enrolled
A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers
Recruiting·SShanghai Argo Biopharmaceutical Co., Ltd.·Phase 1·NCT06917482·40 enrolled
Effect of Some Drugs on Rheumatoid Arithritis Activity
Recruiting·—·Phase 3·NCT03770923·75 enrolled
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06916143·48 enrolled
Page 1 of 25

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)